Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.

Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, Fioramonti J, Cohen M, Bryant AP, Kurtz C, Currie MG, Mayer EA, Bueno L

Neurogastroenterology and motility25 Aug 2009Cited by 147 (Europe PMC)

PMID19706070DOI10.1111/j.1365-2982.2009.01385.xPepBankPUB-19706070

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with TNBS-induced colonic allodynia, linaclotide significantly reduced abdominal contractions during colorectal distension.
In plain wordsIn rats with intestinal inflammation, linaclotide reduced abdominal contractions during colorectal distension.
Peptide
Linaclotide
Outcome
DecreaseAbdominal contractions during colorectal distension
Study
ratn: not reported in source
TNBS-induced colonic allodynia
Outcome group
Pain · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study (rat).
Source sentences
Summary
KEY RESULTS In TNBS-induced colonic allodynia, linaclotide significantly decreased the number of abdominal contractions in response to colorectal distension without affecting the colonic wall elasticity change in response to distending pressures after TNBS.
1 context sentence(design, population, supporting numbers)
Summary · context
METHODS Orally administered linaclotide was evaluated in non-inflammatory acute partial restraint stress (PRS) and acute water avoidance stress (WAS) models in Wistar rats, and in a trinitrobenzene sulfonic acid (TNBS)-induced inflammatory model in Wistar rats and GC-C null mice.
Report a problemFND-1970607001
02AnimalAnimal study (in vivo)Efficacy outcome
In rats after TNBS, linaclotide did not affect colonic wall elasticity changes with distending pressure.
In plain wordsIn rats after TNBS, linaclotide did not change colon wall elasticity during distension.
Peptide
Linaclotide
Outcome
No significant changeColonic wall elasticity
Study
ratn: not reported in source
TNBS-induced colonic allodynia
Outcome group
Pain · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study (rat).
Source sentences
Summary
KEY RESULTS In TNBS-induced colonic allodynia, linaclotide significantly decreased the number of abdominal contractions in response to colorectal distension without affecting the colonic wall elasticity change in response to distending pressures after TNBS.
1 context sentence(design, population, supporting numbers)
Summary · context
METHODS Orally administered linaclotide was evaluated in non-inflammatory acute partial restraint stress (PRS) and acute water avoidance stress (WAS) models in Wistar rats, and in a trinitrobenzene sulfonic acid (TNBS)-induced inflammatory model in Wistar rats and GC-C null mice.
Report a problemFND-1970607002
03AnimalAnimal study (in vivo)Efficacy outcome
In rats under basal conditions, linaclotide did not affect visceral sensitivity.
In plain wordsIn rats under basal conditions, linaclotide did not affect gut sensitivity.
Peptide
Linaclotide
Outcome
No significant changeBasal visceral sensitivity
Study
ratn: not reported in source
Basal conditions
Outcome group
Pain · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study (rat).
Source sentences
Summary
However, linaclotide had no effect on visceral sensitivity under basal conditions.
1 context sentence(design, population, supporting numbers)
Summary · context
METHODS Orally administered linaclotide was evaluated in non-inflammatory acute partial restraint stress (PRS) and acute water avoidance stress (WAS) models in Wistar rats, and in a trinitrobenzene sulfonic acid (TNBS)-induced inflammatory model in Wistar rats and GC-C null mice.
Report a problemFND-1970607003
04AnimalAnimal study (in vivo)Efficacy outcome
In rats exposed to partial restraint stress, linaclotide significantly reduced colonic hypersensitivity.
In plain wordsIn rats exposed to restraint stress, linaclotide reduced colon hypersensitivity.
Peptide
Linaclotide
Outcome
DecreaseColonic hypersensitivity
Study
ratn: not reported in source
Partial restraint stress
Outcome group
Pain · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study (rat).
Source sentences
Summary
In addition, linaclotide significantly decreased colonic hypersensitivity in the PRS and WAS models.
1 context sentence(design, population, supporting numbers)
Summary · context
METHODS Orally administered linaclotide was evaluated in non-inflammatory acute partial restraint stress (PRS) and acute water avoidance stress (WAS) models in Wistar rats, and in a trinitrobenzene sulfonic acid (TNBS)-induced inflammatory model in Wistar rats and GC-C null mice.
Report a problemFND-1970607004
05AnimalAnimal study (in vivo)Efficacy outcome
In rats exposed to water avoidance stress, linaclotide significantly reduced colonic hypersensitivity.
In plain wordsIn rats exposed to water avoidance stress, linaclotide reduced colon hypersensitivity.
Peptide
Linaclotide
Outcome
DecreaseColonic hypersensitivity
Study
ratn: not reported in source
Water avoidance stress
Outcome group
Pain · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study (rat).
Source sentences
Summary
In addition, linaclotide significantly decreased colonic hypersensitivity in the PRS and WAS models.
1 context sentence(design, population, supporting numbers)
Summary · context
METHODS Orally administered linaclotide was evaluated in non-inflammatory acute partial restraint stress (PRS) and acute water avoidance stress (WAS) models in Wistar rats, and in a trinitrobenzene sulfonic acid (TNBS)-induced inflammatory model in Wistar rats and GC-C null mice.
Report a problemFND-1970607005
06AnimalAnimal study (in vivo)Efficacy outcome
In wild-type mice after inflammation, linaclotide significantly reduced hypersensitivity.
In plain wordsIn mice with intact GC-C after inflammation, linaclotide reduced hypersensitivity.
Peptide
Linaclotide
Outcome
DecreasePost-inflammatory hypersensitivity
Study
mousen: not reported in source
Wild-type post-inflammatory mice
Outcome group
Pain · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study (mouse).
Source sentences
Summary
However, in post-inflammatory conditions linaclotide significantly reduced hypersensitivity only in wt mice, but not in GC-C null mice.
1 context sentence(design, population, supporting numbers)
Summary · context
METHODS Orally administered linaclotide was evaluated in non-inflammatory acute partial restraint stress (PRS) and acute water avoidance stress (WAS) models in Wistar rats, and in a trinitrobenzene sulfonic acid (TNBS)-induced inflammatory model in Wistar rats and GC-C null mice.
Report a problemFND-1970607006
07AnimalAnimal study (in vivo)Efficacy outcome
In GC-C null mice after inflammation, linaclotide did not significantly reduce hypersensitivity.
In plain wordsIn mice without GC-C after inflammation, linaclotide did not significantly reduce hypersensitivity.
Peptide
Linaclotide
Outcome
No significant changePost-inflammatory hypersensitivity
Study
mousen: not reported in source
GC-C null post-inflammatory mice
Outcome group
Pain · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study (mouse).
Source sentences
Summary
However, in post-inflammatory conditions linaclotide significantly reduced hypersensitivity only in wt mice, but not in GC-C null mice.
1 context sentence(design, population, supporting numbers)
Summary · context
METHODS Orally administered linaclotide was evaluated in non-inflammatory acute partial restraint stress (PRS) and acute water avoidance stress (WAS) models in Wistar rats, and in a trinitrobenzene sulfonic acid (TNBS)-induced inflammatory model in Wistar rats and GC-C null mice.
Report a problemFND-1970607007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.